Connect to effective hemophilia A treatment
Highly effective in minimally treated and previously untreated patients
In clinical studies:
- 100% of bleeds (N=1047) were controlled with the hemophilia treatment Helixate FS
— 88% of the bleeds were controlled with only 1 or 2 infusions.
- Hemostasis was rated as “excellent” or "good" by the surgeon or treating physician
in 100% of surgical procedures.
Hemostatic control achieved in previously treated hemophilia A, or classic hemophilia,
patients
In clinical studies:
- 100% of bleeds (N=5684) were controlled with Helixate FS — 92.7% of the bleeds
were treated with only 1 or 2 infusions.
- Hemostasis was rated as "excellent" or "good" by the surgeon or treating physician
in 100% of surgical procedures.
Prophylaxis and joint damage risk reduction
Routine prophylaxis demonstrates an 83% reduction in risk of joint damage as compared
to the risk in undergoing hemophilia treatment episodically.
- Children treated episodically had 6 times the likelihood of proven damage to one
or more joints as shown by MRI.
- Children treated with routine prophylaxis had1:
- Approximately 8 times fewer joint hemorrhages and over 5 times fewer total hemorrhages
- No life-threatening bleeds, compared with approximately 9% (3 of 33 children) in
the episodic group
Next: Established Safety
»
1. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic
treatment to prevent joint disease in boys with severe hemophilia. Engl J Med.
2007;357(6):535-544.